学术研究-爱科百发

中文 EN

研发创新

专注于呼吸系统、儿科疾病
创新药物研发和商业化

Molecular mechanism of ziresovir targeting the fusion glycoprotein of respiratory syncytial virus

Yan M, Zou J, Gao Z, et al. PLoS Pathog. Jan 2026

查看详情→
Broad antifibrotic activities of AK3280 in pulmonary, hepatic, cardiac, and skin fibrosis animal models

Gao, Zhao et al. International immunopharmacology. Apr 2025

查看详情→
Efficacy and safety of ziresovir in hospitalised infants aged 6 months or younger with respiratory syncytial virus infection in China: findings from a phase 3 randomised trial with 24-month follow-up

Zhang, HanHu, Cilang et al. The Lancet Child & Adolescent Health. May 2025

查看详情→
Ziresovir in Hospitalized Infants with Respiratory Syncytial Virus Infection

Zhao S, et al. The New England Journal of Medicine. September 2024

查看详情→
Novel small-molecule inhibitors of SARS-CoV-2 main protease with nanomolar antiviral potency

Zhang H, et al. Journal of Infection. February 2024

查看详情→
Current state and challenges in respiratory syncytial virus drug discovery and development

Zou G, et al. Antiviral Research. Jan 2024

查看详情→
A protective human antibody against respiratory syncytial virus by targeting a prefusion epitope across sites IV and V of the viral fusion glycoprotein

Dai L, et al. hLife. November 2023

查看详情→
Safety and efficacy of AK0529 in respiratory syncytial virus-infected infant patients: A phase 2 proof-of-concept trial

Huang LM, et al. Influenza Other Respi Viruses. July 2023

查看详情→
Discovery of Ziresovir as a Potent, Selective, and Orally Bioavailable Respiratory Syncytial Virus Fusion Protein Inhibitor

Zheng XF, et al. Journal of Medicinal Chemistry. July 2019

查看详情→
Comparison of antiviral resistance across acute and chronic viral infections

Mason S, et al. Antiviral Research. October 2018

查看详情→

电话：+86-21-50681677
地址：中国上海市浦东新区盛荣路388弄25号
邮箱：ir@arkbiosciences.com

爱科百发官方公众号

        
首页

电话

顶部